MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research to evaluate various intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Most important trial objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, even thoug... https://charlesa221nyj4.loginblogin.com/profile